Advanced

Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer

Shi, Hong; Bevier, Melanie; Johansson, Robert; Enquist-Olsson, Kerstin; Henriksson, Roger; Hemminki, Kari LU ; Lenner, Per and Försti, Asta LU (2012) In Breast Cancer Research and Treatment 131(3). p.1039-1047
Abstract
MYBL2 is a transcription factor, which regulates the expression of genes involved in cancer progression. In this study, we investigated whether putative functional variants in genes regulating MYBL2 (E2F1, E2F3 and E2F4) or in genes, which are regulated by MYBL2 (BCL2, BIRC5, COL1A1, COL1A2, COL5A2, ERBB2, CLU, LIN9 and TOP2A) affect breast cancer (BC) susceptibility and clinical outcome. Twenty-eight SNPs were genotyped in a population-based series of 782 Swedish BC cases and 1,559 matched controls. BC-specific survival analysis of BIRC5 suggested that carriers of the minor allele of rs8073069 and rs1042489 have a worse survival compared with the major homozygotes (HR 2.46, 95% CI 1.39-4.36 and HR 1.81, 95% CI 1.01-3.25, respectively).... (More)
MYBL2 is a transcription factor, which regulates the expression of genes involved in cancer progression. In this study, we investigated whether putative functional variants in genes regulating MYBL2 (E2F1, E2F3 and E2F4) or in genes, which are regulated by MYBL2 (BCL2, BIRC5, COL1A1, COL1A2, COL5A2, ERBB2, CLU, LIN9 and TOP2A) affect breast cancer (BC) susceptibility and clinical outcome. Twenty-eight SNPs were genotyped in a population-based series of 782 Swedish BC cases and 1,559 matched controls. BC-specific survival analysis of BIRC5 suggested that carriers of the minor allele of rs8073069 and rs1042489 have a worse survival compared with the major homozygotes (HR 2.46, 95% CI 1.39-4.36 and HR 1.81, 95% CI 1.01-3.25, respectively). The poor survival was observed especially in women with aggressive tumours. Multivariate analysis supported the role of rs8073069 as an independent prognostic marker. For BCL2, minor allele carriers of rs1564483 were more likely to have hormone receptor-positive tumours than the major homozygotes. Another SNP in BCL2, rs4987852, was associated with tumour stages II-IV and histologic grade 3. In CLU, the minor allele carriers of rs9331888 were more likely to have tumours with regional lymph node metastasis and stages II-IV than the major homozygotes. In conclusion, our study suggests a role of genetic variation in BIRC5, BCL2 and CLU as progression and prognostic markers for BC, supporting previous studies based on the expression of the genes. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Breast cancer prognosis, MYBL2 interacting genes, Case-control study, Single nucleotide polymorphism
in
Breast Cancer Research and Treatment
volume
131
issue
3
pages
1039 - 1047
publisher
Springer
external identifiers
  • wos:000299346100033
  • scopus:84856211844
ISSN
1573-7217
DOI
10.1007/s10549-011-1826-2
language
English
LU publication?
yes
id
c17354ef-e507-4124-8eb6-5a935b45b610 (old id 2355262)
date added to LUP
2012-03-01 11:27:31
date last changed
2017-11-12 03:38:13
@article{c17354ef-e507-4124-8eb6-5a935b45b610,
  abstract     = {MYBL2 is a transcription factor, which regulates the expression of genes involved in cancer progression. In this study, we investigated whether putative functional variants in genes regulating MYBL2 (E2F1, E2F3 and E2F4) or in genes, which are regulated by MYBL2 (BCL2, BIRC5, COL1A1, COL1A2, COL5A2, ERBB2, CLU, LIN9 and TOP2A) affect breast cancer (BC) susceptibility and clinical outcome. Twenty-eight SNPs were genotyped in a population-based series of 782 Swedish BC cases and 1,559 matched controls. BC-specific survival analysis of BIRC5 suggested that carriers of the minor allele of rs8073069 and rs1042489 have a worse survival compared with the major homozygotes (HR 2.46, 95% CI 1.39-4.36 and HR 1.81, 95% CI 1.01-3.25, respectively). The poor survival was observed especially in women with aggressive tumours. Multivariate analysis supported the role of rs8073069 as an independent prognostic marker. For BCL2, minor allele carriers of rs1564483 were more likely to have hormone receptor-positive tumours than the major homozygotes. Another SNP in BCL2, rs4987852, was associated with tumour stages II-IV and histologic grade 3. In CLU, the minor allele carriers of rs9331888 were more likely to have tumours with regional lymph node metastasis and stages II-IV than the major homozygotes. In conclusion, our study suggests a role of genetic variation in BIRC5, BCL2 and CLU as progression and prognostic markers for BC, supporting previous studies based on the expression of the genes.},
  author       = {Shi, Hong and Bevier, Melanie and Johansson, Robert and Enquist-Olsson, Kerstin and Henriksson, Roger and Hemminki, Kari and Lenner, Per and Försti, Asta},
  issn         = {1573-7217},
  keyword      = {Breast cancer prognosis,MYBL2 interacting genes,Case-control study,Single nucleotide polymorphism},
  language     = {eng},
  number       = {3},
  pages        = {1039--1047},
  publisher    = {Springer},
  series       = {Breast Cancer Research and Treatment},
  title        = {Prognostic impact of polymorphisms in the MYBL2 interacting genes in breast cancer},
  url          = {http://dx.doi.org/10.1007/s10549-011-1826-2},
  volume       = {131},
  year         = {2012},
}